 Scott Younger
Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 4 | 2020 | 50 | 2.020 |
Why?
| | Rare Diseases | 3 | 2022 | 28 | 1.990 |
Why?
| | MicroRNAs | 4 | 2015 | 28 | 1.800 |
Why?
| | Genomics | 6 | 2022 | 58 | 1.770 |
Why?
| | Gene Expression Regulation | 6 | 2017 | 140 | 1.670 |
Why?
| | CRISPR-Cas Systems | 6 | 2021 | 12 | 1.640 |
Why?
| | Neoplasms | 4 | 2021 | 90 | 1.630 |
Why?
| | RNA, Untranslated | 5 | 2015 | 6 | 1.570 |
Why?
| | Enhancer Elements, Genetic | 3 | 2021 | 17 | 1.330 |
Why?
| | Promoter Regions, Genetic | 5 | 2011 | 58 | 1.300 |
Why?
| | DNA Damage | 2 | 2017 | 8 | 1.280 |
Why?
| | Chromatin | 4 | 2017 | 24 | 1.270 |
Why?
| | Humans | 23 | 2022 | 5964 | 0.870 |
Why?
| | Transcription, Genetic | 2 | 2011 | 85 | 0.870 |
Why?
| | Genetic Association Studies | 1 | 2020 | 31 | 0.850 |
Why?
| | RNA, Long Noncoding | 3 | 2015 | 11 | 0.840 |
Why?
| | Fibroblasts | 2 | 2017 | 39 | 0.830 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 145 | 0.790 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 31 | 0.770 |
Why?
| | Algorithms | 2 | 2015 | 96 | 0.650 |
Why?
| | Cell Line, Tumor | 8 | 2021 | 66 | 0.620 |
Why?
| | Centromere | 1 | 2015 | 1 | 0.610 |
Why?
| | DNA, Satellite | 1 | 2015 | 1 | 0.610 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2015 | 9 | 0.610 |
Why?
| | Gene Silencing | 3 | 2011 | 11 | 0.570 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 3 | 0.550 |
Why?
| | Colorectal Neoplasms | 1 | 2014 | 15 | 0.540 |
Why?
| | Animals | 8 | 2021 | 884 | 0.490 |
Why?
| | Binding Sites | 3 | 2020 | 50 | 0.490 |
Why?
| | Cell Proliferation | 3 | 2021 | 68 | 0.440 |
Why?
| | Gene Knockout Techniques | 3 | 2020 | 6 | 0.430 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2022 | 83 | 0.430 |
Why?
| | RNA, Double-Stranded | 2 | 2009 | 2 | 0.410 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 7 | 0.410 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2021 | 106 | 0.410 |
Why?
| | Receptors, Progesterone | 5 | 2011 | 6 | 0.370 |
Why?
| | Cell Line | 4 | 2017 | 104 | 0.370 |
Why?
| | Mice | 6 | 2021 | 441 | 0.360 |
Why?
| | Gene Library | 2 | 2018 | 6 | 0.350 |
Why?
| | 3' Untranslated Regions | 3 | 2015 | 9 | 0.350 |
Why?
| | Genome | 3 | 2022 | 31 | 0.340 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 17 | 0.320 |
Why?
| | Antineoplastic Agents | 3 | 2021 | 44 | 0.310 |
Why?
| | Precision Medicine | 2 | 2021 | 34 | 0.270 |
Why?
| | RNA, Small Interfering | 2 | 2015 | 15 | 0.240 |
Why?
| | Smad4 Protein | 1 | 2021 | 2 | 0.230 |
Why?
| | RNA, Antisense | 3 | 2010 | 3 | 0.230 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 7 | 0.230 |
Why?
| | Nucleocytoplasmic Transport Proteins | 1 | 2021 | 1 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2021 | 74 | 0.220 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2021 | 2 | 0.220 |
Why?
| | Mutation | 2 | 2021 | 202 | 0.220 |
Why?
| | Organ Specificity | 1 | 2020 | 23 | 0.220 |
Why?
| | Biomarkers | 1 | 2020 | 117 | 0.210 |
Why?
| | Regulatory Elements, Transcriptional | 1 | 2020 | 2 | 0.210 |
Why?
| | Phenotype | 1 | 2020 | 217 | 0.200 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2019 | 4 | 0.200 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 35 | 0.200 |
Why?
| | Genetic Variation | 1 | 2020 | 144 | 0.190 |
Why?
| | Genome, Human | 1 | 2020 | 73 | 0.190 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 2 | 2018 | 2 | 0.190 |
Why?
| | Glutathione | 1 | 2019 | 13 | 0.190 |
Why?
| | Antioxidants | 1 | 2019 | 5 | 0.190 |
Why?
| | Cell Survival | 1 | 2019 | 19 | 0.190 |
Why?
| | Retinoblastoma Binding Proteins | 1 | 2018 | 1 | 0.190 |
Why?
| | Aurora Kinase B | 1 | 2018 | 1 | 0.190 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2018 | 2 | 0.190 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2018 | 9 | 0.190 |
Why?
| | Lung Neoplasms | 1 | 2018 | 20 | 0.190 |
Why?
| | Reproducibility of Results | 2 | 2019 | 182 | 0.180 |
Why?
| | Ectopic Gene Expression | 1 | 2018 | 1 | 0.180 |
Why?
| | Lentivirus | 1 | 2018 | 3 | 0.180 |
Why?
| | RNA, Guide | 1 | 2017 | 1 | 0.180 |
Why?
| | Epistasis, Genetic | 1 | 2017 | 3 | 0.180 |
Why?
| | RNA Interference | 1 | 2018 | 11 | 0.180 |
Why?
| | RNA | 2 | 2008 | 19 | 0.170 |
Why?
| | Nucleotide Motifs | 1 | 2017 | 2 | 0.170 |
Why?
| | Doxorubicin | 1 | 2017 | 16 | 0.170 |
Why?
| | Protein Binding | 1 | 2017 | 49 | 0.170 |
Why?
| | Fetus | 1 | 2017 | 24 | 0.170 |
Why?
| | Genetic Testing | 1 | 2017 | 74 | 0.170 |
Why?
| | Sequence Analysis, DNA | 2 | 2022 | 102 | 0.160 |
Why?
| | Proteins | 1 | 2015 | 23 | 0.140 |
Why?
| | Oligonucleotides | 1 | 2015 | 6 | 0.140 |
Why?
| | Cells, Cultured | 1 | 2015 | 113 | 0.140 |
Why?
| | Databases, Genetic | 1 | 2015 | 18 | 0.140 |
Why?
| | Models, Genetic | 2 | 2011 | 18 | 0.130 |
Why?
| | Base Sequence | 2 | 2015 | 114 | 0.130 |
Why?
| | RNA, Messenger | 2 | 2010 | 178 | 0.120 |
Why?
| | RNA-Binding Proteins | 1 | 2010 | 4 | 0.110 |
Why?
| | RNA, Small Cytoplasmic | 1 | 2010 | 1 | 0.110 |
Why?
| | Transcriptional Activation | 1 | 2010 | 14 | 0.110 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 130 | 0.100 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2009 | 3 | 0.100 |
Why?
| | Computational Biology | 1 | 2009 | 27 | 0.100 |
Why?
| | Gene Expression | 1 | 2009 | 74 | 0.100 |
Why?
| | Mice, Nude | 2 | 2019 | 16 | 0.090 |
Why?
| | Apoptosis | 2 | 2018 | 64 | 0.090 |
Why?
| | Signal Transduction | 2 | 2018 | 150 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 101 | 0.070 |
Why?
| | Gene Targeting | 2 | 2017 | 8 | 0.070 |
Why?
| | Pedigree | 1 | 2022 | 52 | 0.060 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 3 | 0.060 |
Why?
| | Molecular Sequence Data | 2 | 2015 | 120 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2021 | 6 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2021 | 15 | 0.060 |
Why?
| | Myeloproliferative Disorders | 1 | 2021 | 9 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2021 | 80 | 0.050 |
Why?
| | Disease Progression | 1 | 2021 | 93 | 0.050 |
Why?
| | Genes, Essential | 1 | 2019 | 2 | 0.050 |
Why?
| | Female | 2 | 2019 | 3320 | 0.050 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 5 | 0.050 |
Why?
| | Datasets as Topic | 1 | 2019 | 7 | 0.050 |
Why?
| | Oncogenes | 1 | 2019 | 26 | 0.050 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 13 | 0.050 |
Why?
| | DNA, Complementary | 2 | 2010 | 18 | 0.050 |
Why?
| | Glutamate-Cysteine Ligase | 1 | 2019 | 1 | 0.050 |
Why?
| | Mammary Glands, Animal | 1 | 2019 | 1 | 0.050 |
Why?
| | Thiocyanates | 1 | 2019 | 1 | 0.050 |
Why?
| | Mammary Glands, Human | 1 | 2019 | 1 | 0.050 |
Why?
| | Ubiquitinated Proteins | 1 | 2019 | 1 | 0.050 |
Why?
| | MCF-7 Cells | 1 | 2019 | 2 | 0.050 |
Why?
| | Organoids | 1 | 2019 | 2 | 0.050 |
Why?
| | Buthionine Sulfoximine | 1 | 2019 | 3 | 0.050 |
Why?
| | Catalytic Domain | 1 | 2019 | 5 | 0.050 |
Why?
| | Aminopyridines | 1 | 2019 | 2 | 0.050 |
Why?
| | Tumor Burden | 1 | 2019 | 5 | 0.050 |
Why?
| | Oxidative Stress | 1 | 2019 | 15 | 0.050 |
Why?
| | Chromosome Segregation | 1 | 2018 | 2 | 0.050 |
Why?
| | Tumor Cells, Cultured | 1 | 2018 | 25 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 16 | 0.050 |
Why?
| | Transduction, Genetic | 1 | 2018 | 3 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2017 | 4 | 0.040 |
Why?
| | Machine Learning | 1 | 2017 | 12 | 0.040 |
Why?
| | Streptococcus pyogenes | 1 | 2017 | 13 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 19 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2015 | 32 | 0.040 |
Why?
| | Child | 1 | 2022 | 2796 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2010 | 15 | 0.030 |
Why?
| | 5' Untranslated Regions | 1 | 2010 | 2 | 0.030 |
Why?
| | BRCA1 Protein | 1 | 2010 | 2 | 0.030 |
Why?
| | Protein Conformation | 1 | 2010 | 10 | 0.030 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2008 | 1 | 0.020 |
Why?
| | Biotin | 1 | 2008 | 2 | 0.020 |
Why?
| | RNA Polymerase II | 1 | 2008 | 5 | 0.020 |
Why?
| | Genetic Techniques | 1 | 2008 | 6 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 98 | 0.020 |
Why?
| | Deoxyadenosines | 1 | 2007 | 1 | 0.020 |
Why?
| | Thionucleosides | 1 | 2007 | 1 | 0.020 |
Why?
| | Peptide Nucleic Acids | 1 | 2007 | 1 | 0.020 |
Why?
| | Hydroxamic Acids | 1 | 2007 | 3 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2007 | 4 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2007 | 4 | 0.020 |
Why?
| | Hormones | 1 | 2007 | 5 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 23 | 0.020 |
Why?
| | Up-Regulation | 1 | 2007 | 28 | 0.020 |
Why?
| | Blotting, Western | 1 | 2007 | 49 | 0.020 |
Why?
| | Histones | 1 | 2007 | 31 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 87 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|